Danazol is used to treat endometriosis, menorrhagia and other menstrual disorders, benign cysts and severe recurrent breast pain, gynecomastia (if other methods are ineffective) and in the long-term treatment of hereditary angioedema.
Mechanism of action
Regression and atrophy of normal and extrauterine endometrial tissue (by suppressing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland)
Abnormal growth rate of abnormal breast tissue
Reduction of attacks associated with hereditary angioedema (by increasing the effective level of complement C4)
Immunological thrombocytopenia 90-14 days
Immunological thrombocytopenia 180-28 days
Plasma peak: 4 hours (2-8 hours)
Metabolism: Extensive liver (to 2-hydroxymethyl danazol and etistron)
Half-life: 9.29 3. 3.29 hours (variable, increases to 24 hours if used long-term in endometriosis).
Excretion: Urine (mostly), feces
In severe liver, kidney and heart disease, thromboembolic disease, vaginal bleeding of unknown cause, androgen-dependent tumors and porphyria should not be used.
Cardiovascular: edema, hot flashes, hypertension, myocardial infarction, palpitations, syncope, tachycardia
Central Nervous System: Depression, Dizziness, Unstable Feelings, Fatigue, Headache, Anger, Drowsiness, Sleep Disorder, Sound Disorder (Dullness, hoarseness, voice instability, sore throat)
Skin: Acne vulgaris, hair loss, increased sweating, maculopapular rash, papular rash, pruritus, dandruff, urticaria, vesicular lesions
Endocrinology and metabolism: amenorrhea (may continue after treatment), changes in libido, decreased glucose tolerance (and glucagon changes), decreased HDL cholesterol, decreased thyroxine-binding globulin (TBG), mild hirsutism. Increased LDL cholesterol, Increased thyroxine-binding globulin (TBG), Menstrual disorders (Changed cycle time, Spotting), Weight gain
Gastrointestinal: constipation, gastroenteritis, nausea, vomiting
Genitourinary: Asthenospermia (reduced progressive sperm motility), Breast atrophy, Decreased ejaculation volume, Blood in urine, Inhibition of spermatogenesis, Sperm disorders (changes in sperm count and semen viscosity), Vaginal dryness, Vaginal tenderness
Hematology and oncology: Abnormal erythrocytes (increased), decreased sex hormone-binding globulin (SHBG), increased eosinophil levels, increased sex hormone-binding globulin (SHBG), leukocytosis, leukopenia, long-term malignant tumor Duration), Petechiae, Polycythemia, Purpura, Thrombocytopenia, Increased platelet count
Hepatic: cholestatic jaundice, hepatic adenoma, hepatic tumor (malignant, after prolonged use), increased liver enzymes, jaundice, hepatic pleurisy
Neuromuscular and musculoskeletal: ankylosing spondylitis, joint pain, low back pain, increased creatine phosphokinase, joint swelling, arm and leg pain, muscle cramps, muscle spasm, neck pain, tremor, weakness
Ocular: Visual disorders
Respiratory: Interstitial pneumonia
CYP3A4 Inhibitor (Medium)
Intensifying the antihypertensive effects
Exacerbation of hypoglycemia
Category X Interactions (Avoidance)
Reducing the effects of drugs by danazol:
Reducing the effects of danazol by drugs:
No significant interference has been identified.
Enhancing the effects of drugs with danazol:
Ajmaline, atorvastatin, C1 inhibitors, carbamazepine, cyclosporine (systemic), dofetilide, flibanserin, limburoxant, lumitapid, nimodipine, pimozide, simvastatin, tacrolimus (systemic and localized, anabrigant, diethygone)
Increased effects of danazol by drugs:
Consumption with food delays the time to reach the maximum serum level.
Eating a high-fat meal increases the plasma concentration and bioavailability of the drug.
- Beta pregnancy testing is required before starting treatment.
- The patient’s liver and kidney function should be monitored periodically.
- Evaluate hematological parameters, lipid status, symptoms of intracranial hypertension (swelling of the optic disc, headache, nausea, vomiting), androgen changes and / or fluid retention in the patient.
- It is necessary for the patient in terms of hypertension, high intracranial pressure (headache, nausea, vomiting, changes in vision), hepatotoxicity (jaundice, loss of appetite, dizziness), thrombotic events (chest pain, visual disturbances, leg pain) (Stroke symptoms), elevated LDL levels, CNS changes, and hematuria are monitored and the patient is warned to report these symptoms promptly.
- Patients with diabetes should be advised to monitor their blood sugar closely.
- Teach the patient the correct method of breast examination by the person himself.
- Monitor patient CBC.
Hereditary angioedema (long-term use):
- CBC, urinalysis, liver function and fat status of the patient should be monitored at the beginning of treatment and then every 6 months during the treatment period and 6 months after discontinuation of the drug.
- Ultrasound monitoring of the liver is necessary at the beginning of treatment and then annually.
- The patient’s blood pressure should be monitored every 6 months.
Periodic breast pain associated with benign breast disorders:
Monitor the patient for pain and other side effects (usually at 1, 3, and 6 months of treatment).
- Light-sensitive reactions may occur.
- If pregnancy is possible, stop taking the medicine and call your doctor.
Was this helpful?
0 / 0